CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
供者淋巴细胞输注治疗移植后病毒感染后的急性神经系统受累：与新型癌症免疫治疗相关 CNS 毒性相同的模式？
英文原题：Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?
查看英文原题
Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
移植早期是造血干细胞移植（HSCT）成功的关键阶段。新发病毒感染以及与受者T细胞免疫完全清除和供者来源系统重建效率低下相关的再激活，是HSCT的主要风险。迄今为止，针对HSCT后病毒感染相关并发症的药物治疗有许多局限性。过继性细胞治疗（ACT）代表一种新的药物治疗策略，使我们能够在HSC移植后重建针对感染性病原体的免疫应答。为证明这种新型免疫治疗策略的潜在优势，我们报告三例儿科患者及各自在供者淋巴细胞输注后的中枢神经系统并发症。
展开英文摘要原文
Early post-transplant is the critical phase for the success of hematopoietic stem cell transplantation (HSCT). New viral infections and the reactivations associated with complete ablation of the recipient's T-cell immunity and inefficient reconstitution of the donor-derived system represent the main risks of HSCT. To date, the pharmacological treatments for post-HSCT viral infection-related complications have many limitations.
Adoptive cell therapy (ACT) represents a new pharmacological strategy, allowing us to reconstitute the immune response to infectious agents in the post-HSC period. To demonstrate the potential advantage of this novel immunotherapy strategy, we report three cases of pediatric patients and the respective central nervous system complications after donor lymphocyte infusion.
论文信息
- 作者
- Marcuzzi A、Rimondi E、Melloni E、Zennaro F、Sonzogni A、Leo S、Maximova N
- 第一作者单位
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.Italy
- 通讯作者单位
- Bone Marrow Transplant Unit, Institute for Maternal and Child Health-IRCCS Burlo Garofolo, 34137 Trieste, Italy.Italy
- 文献类型
- 病例报告
- 期刊
- International journal of molecular sciences2022 Mar 24
- 原文标识
- PubMed 35408912 · DOI 10.3390/ijms23073553
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →